Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Neurontin prescriptions surge amid opioid crisis

Prescriptions for nerve pain medicines like Neurontin and Lyrica more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests.

Read More »

Drugmakers raise 2018 U.S. prices

2018 opened with elevated U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit.

Read More »

New drug approvals hit 21-year high in 2017

U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light — more than double the previous year — while the figure also rose in the EU.

Read More »

China: U.S. should do more to cut opioid demand

The United States should take action to reduce demand for the drugs fueling its deadly opioid crisis, a top Chinese drug control official said.

Read More »

Teva Announces Exclusive U.S. Launch of Generic Version of Reyataz

Teva Pharmaceutical Industries Ltd. announced the exclusive launch of a generic version of Reyataz (atazanavir) capsules in the U.S.

Read More »

Kyprolis improves overall survival in blood cancer

Amgen Inc. said a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Read More »

PhRMA sues to stop California drug price law

The trade group representing U.S. drugmakers filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices.

Read More »

U.S. healthcare spending growth slowed in 2016

Growth in healthcare spending in the United States slowed in 2016 following two years of expansion under the Affordable Care Act.

Read More »

Exclusive: U.S. health regulator Verma eyes new methods for drug pricing

The U.S. government is considering setting new payment methods aimed at curbing costs for Medicare and Medicaid coverage of breakthrough medical treatments with very high prices, particularly novel gene-based therapies for cancer and other diseases, a top health official said.

Read More »

Azar says drug pricing a top priority

Alex Azar – a former drug industry exec who Republicans nominated to run the Department of Health and Human Services – promised to lower drug prices that he said are too high, saying he would look at abuse of patent laws that delays generic competition.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom